Can-Fite BioPharma (CANF) AI Stock Analysis

• Market Cap: $15.93M
• Dividend Yield: N/A
• Average Volume (3M): 95.71K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.45
• Revenue Growth: N/A
• EPS Growth: N/A
• Country: US
• Employees: 5
• Sector: Healthcare
• Sector Strength: 78
• Industry: Biotechnology
• EPS (TTM): -1.86
• Shares Outstanding: 10,211,680
• 10 Day Avg. Volume: 60,984
• 30 Day Avg. Volume: 95,709
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): 55.70
• Price to Cash Flow (P/CF): N/A
• P/FCF Ratio: 0.00
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: $10.00
• Price Target Upside: 545.16% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 1

The overall score of 42 reflects significant financial challenges, including persistent losses and negative cash flows. Technical indicators suggest a bearish trend, and valuation metrics are unattractive due to negative earnings. The absence of earnings call highlights and corporate events adds uncertainty, necessitating strategic improvements for investor confidence.

Can-Fite BioPharma Business Overview & Revenue Model

Company Description

Can-Fite BioPharma Ltd. is a clinical-stage biopharmaceutical company focused on the development of orally bioavailable small molecule therapeutic products targeting cancer and inflammatory diseases. The company's core sectors include biotechnology and pharmaceuticals, with a primary emphasis on developing innovative treatments for autoimmune inflammatory diseases, liver conditions, and oncology. Can-Fite's leading drug candidates, Piclidenoson and Namodenoson, are designed to target and modulate key pathways in inflammatory and cancerous diseases.

How the Company Makes Money

Can-Fite BioPharma generates revenue primarily through licensing agreements, milestone payments, and royalties associated with its drug candidates. The company forms strategic partnerships with larger pharmaceutical companies to co-develop and commercialize its therapeutic products. These partnerships often involve upfront payments and continuous funding for research and development in exchange for certain commercialization rights. Additionally, Can-Fite seeks to out-license its drug candidates to partners who have the resources to advance them through the later stages of clinical trials and into the market. The company also benefits financially from grants and research funding aimed at supporting its pipeline development. However, as a clinical-stage company, it does not yet generate revenue from product sales.

Can-Fite BioPharma Financial Statement Overview

Summary

Can-Fite BioPharma faces financial difficulties with declining revenues, persistent losses, and negative cash flows. The company benefits from low debt levels but struggles with operational inefficiencies and needs strategies for revenue growth.

Income Statement

Can-Fite BioPharma's income statement reveals significant challenges, with a declining revenue trend over the years and negative profitability. The gross profit margin remains stable at 100% due to negligible costs, but negative EBIT and net profit margins highlight persistent operational losses. Revenue growth is weak, indicating a need for strategic adjustments to improve financial performance.

Balance Sheet

The balance sheet shows moderate stability with a relatively low debt-to-equity ratio, thanks to minimal debt levels. However, the return on equity is negative due to consistent net losses, undermining equity value. The equity ratio is reasonable, suggesting a fair capital structure, but the company needs to leverage its assets more efficiently.

Cash Flow

Cash flow analysis indicates a challenging scenario with negative operating and free cash flows, reflecting cash burn. The operating cash flow to net income ratio is negative, highlighting a reliance on financing activities to sustain operations. Improvement in operational efficiency is necessary to achieve sustainable cash flows.

Breakdown
TTM	Dec 2023	Dec 2022	Dec 2021	Dec 2020	Dec 2019
Income Statement		Total Revenue
667.00K	743.00K	810.00K	853.00K	763.00K	2.03M
	Gross Profit
667.00K	743.00K	810.00K	853.00K	763.00K	2.03M
	EBIT
-7.79M	-8.20M	-10.10M	-12.84M	-14.14M	-12.01M
	EBITDA
-7.78M	-8.18M	-10.08M	-12.83M	-14.13M	-11.99M
	Net Income Common Stockholders
-7.37M	-7.63M	-10.17M	-12.62M	-14.44M	-12.63M
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
3.89M	8.92M	7.98M	19.14M	8.34M	2.76M
	Total Assets
7.95M	9.99M	9.28M	20.25M	9.52M	8.17M
	Total Debt
0.00	40.00K	62.00K	124.00K	67.00K	75.00K
	Net Debt
-3.62M	-4.24M	-2.92M	-4.27M	-8.20M	-2.62M
	Total Liabilities
4.94M	3.75M	4.81M	5.87M	3.45M	5.73M
	Stockholders Equity
3.02M	6.24M	4.47M	14.38M	6.07M	2.44M
Cash Flow		Free Cash Flow
-4.04M	-8.44M	-10.81M	-9.87M	-12.09M	-10.84M
	Operating Cash Flow
-4.04M	-8.44M	-10.80M	-9.86M	-12.06M	-10.83M
	Investing Cash Flow
4.50M	498.00K	9.50M	-14.51M	-26.00K	-253.00K
	Financing Cash Flow
0.00	9.14M	20.46M	20.46M	17.68M	10.17M

Can-Fite BioPharma Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 1.55
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CANF, the sentiment is Negative. The current price of 1.55 is below the 20-day moving average (MA) of 1.65, below the 50-day MA of 1.59, and below the 200-day MA of 2.22, indicating a bearish trend. The MACD of >-0.01 indicates Positive momentum. The RSI at 44.04 is Neutral, neither overbought nor oversold. The STOCH value of 22.76 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for CANF.

Can-Fite BioPharma Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
CPRX	76 Outperform	$2.55B	16.02	29.38%	―	23.49%	104.96%
PLX	68 Neutral	$166.41M	―	-27.18%	―	-28.22%	-197.63%
CHRS	55 Neutral	$121.68M	6.02	0.51%	―	3.78%	―
CYRX	49 Neutral	$331.90M	―	-25.76%	―	-2.09%	-13.01%
Sector *	49 Neutral	$6.90B	0.01	-53.76%	2.46%	24.91%	-3.11%
CANF	42 Neutral	$15.93M	―	-122.28%	―	―	―
GALT	36 Underperform	$99.69M	―	48.74%	―	―	4.53%